On Friday, SpringWorks Therapeutics Inc (NASDAQ: SWTX) opened lower -0.47% from the last session, before settling in for the closing price of $44.93. Price fluctuations for SWTX have ranged from $28.21 to $62.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 663.47% over the past five years. Company’s average yearly earnings per share was noted 34.95% at the time writing. With a float of $70.37 million, this company’s outstanding shares have now reached $74.40 million.
Let’s look at the performance matrix of the company that is accounted for 368 employees. In terms of profitability, gross margin is 93.07%, operating margin of -145.17%, and the pretax margin is -134.73%.
SpringWorks Therapeutics Inc (SWTX) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of SpringWorks Therapeutics Inc is 6.15%, while institutional ownership is 105.97%. The most recent insider transaction that took place on Mar 03 ’25, was worth 1,084,592. In this transaction Chief Operating Officer of this company sold 20,000 shares at a rate of $54.23, taking the stock ownership to the 169,712 shares. Before that another transaction happened on Mar 03 ’25, when Company’s Chief Executive Officer sold 49,000 for $54.24, making the entire transaction worth $2,657,656. This insider now owns 954,869 shares in total.
SpringWorks Therapeutics Inc (SWTX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.71 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 34.95% per share during the next fiscal year.
SpringWorks Therapeutics Inc (NASDAQ: SWTX) Trading Performance Indicators
Check out the current performance indicators for SpringWorks Therapeutics Inc (SWTX). In the past quarter, the stock posted a quick ratio of 3.70. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 17.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.48, a number that is poised to hit -0.76 in the next quarter and is forecasted to reach -0.42 in one year’s time.
Technical Analysis of SpringWorks Therapeutics Inc (SWTX)
SpringWorks Therapeutics Inc (NASDAQ: SWTX) saw its 5-day average volume 4.7 million, a positive change from its year-to-date volume of 2.6 million. As of the previous 9 days, the stock’s Stochastic %D was 88.21%. Additionally, its Average True Range was 2.89.
During the past 100 days, SpringWorks Therapeutics Inc’s (SWTX) raw stochastic average was set at 42.49%, which indicates a significant decrease from 88.86% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 73.76% in the past 14 days, which was lower than the 83.74% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $47.43, while its 200-day Moving Average is $39.37. Nevertheless, the first resistance level for the watch stands at $45.09 in the near term. At $45.46, the stock is likely to face the second major resistance level. The third major resistance level sits at $45.91. If the price goes on to break the first support level at $44.27, it is likely to go to the next support level at $43.82. Assuming the price breaks the second support level, the third support level stands at $43.45.
SpringWorks Therapeutics Inc (NASDAQ: SWTX) Key Stats
There are currently 74,984K shares outstanding in the company with a market cap of 3.35 billion. Presently, the company’s annual sales total 191,590 K according to its annual income of -258,130 K. Last quarter, the company’s sales amounted to 61,550 K and its income totaled -77,300 K.
